StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital initiated coverage on shares of InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target for the company.

InspireMD Price Performance

Shares of NYSE:NSPR opened at $2.80 on Tuesday. The company has a market cap of $83.13 million, a price-to-earnings ratio of -3.73 and a beta of 0.88. InspireMD has a one year low of $1.81 and a one year high of $3.80. The firm has a fifty day moving average price of $2.86 and a two-hundred day moving average price of $2.76.

Hedge Funds Weigh In On InspireMD

A number of large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC purchased a new position in shares of InspireMD in the fourth quarter valued at about $27,000. Legato Capital Management LLC purchased a new stake in shares of InspireMD in the 4th quarter worth approximately $47,000. Schonfeld Strategic Advisors LLC grew its stake in shares of InspireMD by 153.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock worth $79,000 after acquiring an additional 18,233 shares during the last quarter. Northern Trust Corp increased its stake in InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after purchasing an additional 24,452 shares in the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in shares of InspireMD during the fourth quarter valued at approximately $191,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.